For example, aromatase inhibitors are the primary therapy for breast cancer with overexpression of estrogen receptors (ERs) [19], but it has been reported that resistance to aromatase inhibitors can involve the activation of a very distinct signaling, the one mediated by HER2 [20]. Here, CYP19A1 is linked to breast carcinoma.